India Pharma Outlook Team | Friday, 19 June 2026
Moderna flu vaccine moved a step closer to market approval after an independent panel of advisers to the US Food and Drug Administration (FDA) unanimously backed the company's experimental shot for adults aged 50 years and older.
The positive recommendation marks a major milestone for Moderna as it expands its vaccine portfolio beyond COVID-19 products.
The Moderna flu vaccine received a 9-0 vote from the FDA's Vaccines and Related Biological Products Advisory Committee, which concluded that the benefits of the vaccine outweigh its risks. The decision brings Moderna closer to securing approval for what could become the first mRNA-based seasonal influenza vaccine in the United States.
The advisory committee reviewed data from a large late-stage clinical trial involving nearly 40,000 adults aged 50 years and above. According to trial results, the vaccine demonstrated approximately 27% higher efficacy in preventing influenza compared with a licensed standard-dose seasonal flu vaccine.
Key highlights from the review include:
Moderna is seeking traditional approval for adults aged 50 to 64 years and accelerated approval for those aged 65 years and older. The company is expected to conduct additional studies to confirm clinical benefits in older adults.
Also Read: Scaling Perfusion Technology from Lab Success to Manufacturing Reality
The vaccine uses the same messenger RNA (mRNA) technology that helped Moderna develop its COVID-19 vaccine. Unlike traditional flu vaccines, which are often produced using egg-based manufacturing methods, mRNA vaccines can be designed and produced more quickly.
Health experts believe this technology could help vaccine manufacturers respond faster to changing influenza strains and improve the match between vaccines and circulating viruses.
The FDA's review documents noted that mRNA technology may offer manufacturing advantages and greater flexibility in updating vaccine formulations when needed.
The committee's recommendation is not binding, but FDA regulators typically consider advisory panel decisions carefully during the final approval process.
The endorsement comes at an important time for Moderna as demand for COVID-19 vaccines continues to moderate. The company has been investing heavily in expanding its pipeline across respiratory diseases, cancer treatments, and other infectious diseases.
A successful approval could strengthen Moderna's position in the highly competitive influenza vaccine market and support future products, including combination vaccines that target both influenza and COVID-19 in a single shot.
The FDA is expected to make a final decision on the vaccine by August 2026. If approved, the product would represent another major commercial opportunity for Moderna and further validate the use of mRNA technology beyond the pandemic.
Moderna is a US-based biotechnology company focused on developing medicines and vaccines using messenger RNA (mRNA) technology. The company gained global recognition through its COVID-19 vaccine and is advancing a broad pipeline across infectious diseases, oncology, and rare disorders.
.jpg)
